Chairman of the Board, Interim CEO, CBDO
With more than 30 years of brand and product development experience in the nutraceutical, pharmaceutical, and medical device sectors, Mr. Edalat brings a keen eye for business development and growth opportunities to Vivera. His forward-thinking management approach as interim CEO has seen Vivera grow from a single division at its founding to over seven divisions and counting today.
Leading Vivera’s business development domestically and internationally, Mr. Edalat works closely with Vivera’s sales and marketing teams to anticipate and meet market demands. With trusted global relationships built over the decades, Mr. Edalat has worked to leverage his connections and expand Vivera’s reach. At home, he has led the Company through innovative research and development, focusing on maintaining Vivera’s core mission – putting patients first.
Gregory P. Hannley
Chief Recovery Officer, Board of Directors
As both a successful entrepreneur and investor, Mr. Hannley has spent his career helping those who need it most. Founder of the Soba Recovery Centers, Mr. Hannley is aware how critical high quality and competent in-patient services are for addiction treatment. His model takes a full-service holistic approach to not only treat drug and alcohol addiction, but to address the underlying causes. He is a passionate advocate for addiction treatment and alternative therapies to assist in the recovery of those afflicted.
Mr. Hannley has appeared on Larry King Live and 20/20.
Chief Operations Officer
With over 20 years of comprehensive operations and business development experience, Mr. Demman has spent his career building and maintaining relationships across the board. He is well-versed in the needs of high volume, high profile, companies. His expertise in crafting programs aimed at increasing revenue and growth while maintaining strong relationships with government, regulators, and stakeholders makes Mr. Demman the ideal candidate to oversee the day-to-day operations of Vivera while working with the Executive team on long term growth strategies.
Interim Chief Financial Officer
Mr. Fagan has over two decades of experience in accounting, financial reporting, and risk management. His career has spanned a host of organizations, from mid-market firms to Fortune 100 powerhouses, he is well prepared to lead Vivera’s financial team as it grows. He has significant audit and financial reporting experience, including US GAAP and SEC reporting, having worked closely with public companies. With over 10 years of manufacturing and technology expertise, Mr. Fagan is a skilled communicator and leader.
Co-Founder and Director
Ms. Karpinski is the Vice President of Sales and Marketing for Vivera Pharmaceuticals. Passionate about public health, Olivia has been in the healthcare industry for over 10 years. Her multifaceted expertise in product knowledge and business development helps her lead the sales team for Vivera while always seeking new, synergistic opportunities for the Company. Ms. Karpinski was formerly a Senior Business Analyst in the Medical Special Investigations Unit at Fortune 100 Company, Liberty Mutual. She is Lean Six Sigma certified and certified by the National Insurance Crime Bureau in special investigations and major medical fraud.
Stephen J. McColgan, M.D. MBA
Chief Medical Officer
Dr. McColgan was one of the first surgeons to perform Laparoscopic Cholecystectomy, Laparoscopic Nissen Fundoplication, and Laparoscopic Gastric bypass in the Southern California area. His multi-decade experience as not only a premier surgeon but as a successful entrepreneur bring a highly desirable mix of science and business to Vivera’s executive team. Before co-founding Endodynamix, Inc., Dr. McColgan spent 10 years as the Chairman for the Department of Surgery at Bellflower Medical Center in Southern California. Currently Dr. McColgan is a lecturer at University of California Riverside’s School of Medicine. As part of Vivera’s medical advisory team, Dr. McColgan works with the regulatory and scientific teams to develop protocols, novel products, and guide Vivera towards new horizons in healthcare.
Mehdi Hatamian, Ph.D.
Senior Scientific Advisor, Interim Chief Scientific Officer
As former NASA Space Shuttle program engineer and a 20-year career at Broadcom as the Chief Scientist for Central Engineering, Dr. Hatamian brings an engineer’s mindset to Vivera. With over 100 issued patents, and the publisher of 50 scientific papers, he is a scientist at heart. Dr. Hatamian works closely with Vivera’s team to expand our Medical Technology and Medical Device divisions, bringing not only his engineering expertise but his knowledge of medical research. Dr. Hatamian is the founder and CEO of 2Pi-Sigma, a biomedical firm working on next-generation cancer detection devices and technologies.
Charles S. Freeman
Director of Corporate Security
After 34 years in law enforcement, Mr. Freeman joined Vivera after retiring as a Police Sergeant. He is a highly skilled investigator and experienced professional who works closely with the executive team to ensure both operational and digital security for the Company. For most of his career with Newport Beach Police Department, Mr. Freeman oversaw the Special Investigations Unit, requiring him to maintain a security clearance with the FBI. Mr. Freeman ensures the day-to-day physical security of the Company, and works with the team to ensure that every aspect of Vivera’s operations are well secured.
Regulatory Compliance Director
Mr. Hijazi spent his career of over three decades overseeing quality and process engineering in some of the largest pharmaceutical manufacturing facilities in the country. He has worked closely with the FDA on numerous medical devices and pharmaceutical products as a regulatory and compliance lead, and is well acquainted with the 510K and de novo medical device filing processes. Mr. Hijazi is a detail-oriented leader with expertise in Lean Manufacturing and Six Sigma. He brings his decades of regulatory compliance and product development expertise to Vivera and helps guide not only the Company’s regulatory team, but works collaboratively in leading clinical trial and new product development efforts.